<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="275">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01135069</url>
  </required_header>
  <id_info>
    <org_study_id>RAM-01</org_study_id>
    <nct_id>NCT01135069</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo</brief_title>
  <official_title>Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spear Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spear Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective will be to assess clinical bioequivalence of 0.1% Retin-A Micro® Gel and Spear
      Pharmaceutical's generic 0.1% Tretinoin Microsphere Gel with a placebo arm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not required
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement in Acne</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Counting of acne lesions both inflammatory and non-inflammatory</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Generic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment of acne for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brand</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of acne for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment if acne for 12 weeks as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tretinoin microsphere 0.1%</intervention_name>
    <description>Treatment of acne vulgaris</description>
    <arm_group_label>Generic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brand Retin-A Micro tretinoin microsphere gel 0.1%</intervention_name>
    <description>Treatment of acne vulgaris</description>
    <arm_group_label>Brand</arm_group_label>
    <other_name>Retin-A Micro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo microsphere gel</intervention_name>
    <description>treatment of acne vulgaris</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal, healthy male and female children and adult

          -  Written and verbal informed consent must be obtained. Patients age 12 to 17
             (inclusive) must sign an assent for the study and a parent or a legal guardian must
             sign the informed consent.

          -  Women of child-bearing potential must be non-pregnant and non-nursing, and must be
             willing to avoid pregnancy during the course of the study and during the menstrual
             cycle following completion of their participation in the study.

          -  Able to refrain from the use of all other topical acne medications or antibiotics
             during the treatment period.

          -  Considered reliable and capable of understanding their responsibility and role in the
             study.

        Exclusion Criteria:

          -  Significant history or clinical evidence of auto-immune, cardiovascular,
             gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.

          -  Abnormal pre-existing skin condition which might affect the normal course of acne
             vulgaris (e.g., eczema, psoriasis, albinism, or chronic vesiculobullous disorders).

          -  Use topical acne therapy during the two week period prior to study initiation.

          -  Use of systemic retinoid treatment within six months prior to study initiation.

          -  Pregnant or breast-feeding.

          -  Serious psychological illness.

          -  Participation in any clinical research study during the 30 day period preceding study
             initiation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Krunal Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moore Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moore Clinical Research</name>
      <address>
        <city>Land O Lakes</city>
        <state>Florida</state>
        <zip>34628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 15, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2010</firstreceived_date>
  <firstreceived_results_date>May 28, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
